Is cannabidiol worth a trial in Rasmussen encephalitis?

Eur J Paediatr Neurol. 2022 Mar:37:53-55. doi: 10.1016/j.ejpn.2022.01.008. Epub 2022 Jan 11.

Abstract

We report 3 patients (age 8, 13 and 14 years) with drug-resistant epilepsy due to Rasmussen encephalitis treated with cannabidiol in addition to their current antiseizure medication (ASM). In all three patients we observed a positive effect, which seemed to surpass the efficacy that would be expected from a different fourth or fifth antiseizure drug used during the course of the disease.

Keywords: Cannabidiol; Drug resistant epilepsy; Epilepsy; Rasmussen encephalitis.

MeSH terms

  • Anticonvulsants / therapeutic use
  • Cannabidiol* / therapeutic use
  • Drug Resistant Epilepsy* / drug therapy
  • Drug Resistant Epilepsy* / etiology
  • Encephalitis* / drug therapy
  • Humans
  • Inflammation

Substances

  • Anticonvulsants
  • Cannabidiol